---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023481"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T06:20:15.298018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vericel records Q1 MACI revenue $46.3M (+15% YoY), raises FY profitability guidance

## Summary
- Record Q1 MACI revenue $46.3M (+15% YoY); total revenue $52.6M vs $51.3M YoY.
- Net loss $11.2M ($0.23/diluted) vs $3.9M loss ($0.08) YoY; adjusted EBITDA $3.2M vs $7.2M.
- Full-year revenue growth reaffirmed 20-23%; raised gross margin guidance to 74% and adjusted EBITDA margin to 26%.
- ~400 MACI Arthro surgeons trained; YTD biopsy growth >30% for trained surgeons; NexoBrid +207% YoY.
- Cash $162M, no debt; tariffs expected negligible impact.

## SEC filing metadata
- accession: 0001628280-25-023481
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/0001628280-25-023481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828025023481/vcel-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023481
- JSON: https://secwatch.observer/filing/0001628280-25-023481.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.